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Abstract: 
Background: The potential of microRNAs (miRNAs) as bedside biomarkers in selecting 
newborns with hypoxic-ischemic encephalopathy (HIE) for neuroprotection has yet to be 
explored. Commonly, blood-based biomarker tests use plasma or serum which don’t 
allow evaluation of both intracellular and extracellular changes.  
Methods: We describe a technique to extract and compare expression of miRNAs from 
a single small 6 mm diameter dried blood spot (DBS) stored at room temperature with 
those from EDTA-blood, plasma and urine. Three miRNAs (RNU6B, let7b and miR-
21RNA) were quantified via extraction and quantitative RT-PCR performed from a DBS 
and compared with levels from EDTA-blood, plasma and urine. Secondarily, candidate 
miRNAs let7b, miR21, miR-29b, miR-124 and miR-155 in DBS were evaluated as 
potential biomarkers for HIE.  
Results:  Candidate miRNAs were extractable in all biosamples from newborns, with 
the highest expression in DBS. There was a good correlation between miRNAs levels in 
DBS and EDTA-blood at -80oC. No significant difference was observed in the miRNA 
levels between the favorable and unfavorable outcome groups for babies with HIE.  
Conclusions: Dried blood spots may be useful for studying the potential of miRNAs as 
biomarkers for brain injury. 
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Introduction: 
The lack of more effective methods in selecting babies for neuroprotection and the need 
for prognostication for outcomes after hypoxic-ischemic encephalopathy (HIE) pose 
major challenges to clinicians, patient families and the economy. At present there is no 
effective tissue biomarker at the bedside to allow selection of babies for neuroprotection 
within the narrow therapeutic window or for early prognostication of outcomes. A single 
or a panel of biomarkers with high sensitivity and specificity that is reliable and 
reproducible at the bedside would be extremely valuable in selecting babies for 
appropriate interventions. Biomarkers allow objective measurement and evaluation of 
biological and pathological response to therapeutic intervention (1). Biological sample 
(biosample) based biomarkers hold much promise with many potential advantages; 
these are bedside tests, extraction is relatively quick, easy and cheap and the 
technology involved in analysis has developed rapidly with small volumes of tissue 
required. 
 
In all CNS injuries, whether in adults, children or newborns, biosample-based biomarker 
studies have been carried out mostly on blood samples as well as on urine or 
cerebrospinal fluid (CSF). Blood based biomarker studies have commonly been 
performed on plasma or serum components (2) and have not analyzed whole blood or 
the cellular components. However, using plasma or serum exclusively is limited by the 
need for long term cold storage (e.g. -80oC), cellular debris contamination, hemolysis, 
and analysis confined to only extracellularly released components within the blood. 
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Blood sampling in newborns can be challenging due to the small size of the infant, with 
technical difficulty in vascular access and/or obtaining sufficient volume of non-
hemolyzed blood. Dried blood spots (DBS), typically obtained from a heel prick and 
allowing drops of blood to settle onto absorbent paper, have been routinely used in 
newborn babies in the first week of life for mass screening and early detection of 
multiple diseases including cystic fibrosis, congenital hypothyroidism and inborn errors 
of metabolism (3). The use of DBS to assay biomarkers of brain injury in newborns has 
yet to be fully explored. Protein biomarkers such as inflammatory molecules, cell 
structures or trophic factors have been explored in newborns with HIE, but their 
effectiveness as successful biomarkers in the clinical setting remains to be determined 
(2, 4). In this study, we report our method of extracting microRNAs (miRNAs) from DBS 
stored at room temperature. 
 
MiRNAs are endogenous short non-coding single-stranded RNA molecules made up of 
18 - 22 nucleotides, which are important in the regulation of gene expression post-
transcription (5). They appear to function by binding to the 3’-untranslated region of 
messenger RNAs (mRNA) from target protein-coding genes leading to gene silencing 
by mRNA cleavage, translational repression and deadenylation (6). They have been 
found to influence varying stages of neurogenesis, including cell differentiation, 
proliferation and synaptogenesis from in vitro and in vivo studies (7). Studies of miRNAs 
in mice and humans have shown that approximately 70% of identified miRNAs are 
expressed in brain tissue, in relation to the complexity of the nervous system and its 
connections (8-10).  
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However, the physiological and pathophysiological role of miRNA in newborns remains 
to be fully determined. With organs such as the brain still developing, it is likely that the 
expression of miRNA in newborns is distinctive, yet related to their counterparts in 
adults based on their regulatory role. RNU6B belongs to a class of small nucleolar RNA 
and is frequently used as an “endogenous control” to normalize miRNA expression 
studies. Let7b and miR-21 have both been shown to be important in adult brain 
pathology following trauma in animal studies (11-12), ischemia/stroke (13-14), and 
Alzheimer’s disease (15-16).  Recently, miR-29b which is activated during neuronal 
maturation has been linked to inhibition of neuronal apoptosis (17). Brain specific 
miRNA 124 has been well noted to influence the nervous system in a number of 
conditions including nervous system development, neurodegeneration, CNS stress, 
stroke, neuro-immunity and brain tumors (18). It has been shown to influence 
neurodevelopment by triggering brain-specific alternative pre-mRNA splicing (19). 
Additionally, miRNA 124 has been shown to predict neurological outcome following 
cardiac arrest in adults (20). MiRNA 155 has been shown to be involved in microglia-
mediated immune response (21). To date, the role of these miRNAs in newborns 
remains to be determined.  
 
We set out to prospectively (i) extract sufficient total RNA from a single DBS stored in 
room temperature from newborn babies admitted to the neonatal unit after suspected 
hypoxia-ischemia; (ii) quantify the expression of three selected miRNAs (RNU6B, Let7b 
and miR-21) in DBS compared to those in EDTA-blood, plasma and urine using 
quantitative RT-PCR and to (iii) explore the role of five selected miRNAs (Let7b, miR-
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21, miR-29b, miR-124a and miR-155) normalized to RNU6B (putative endogenous 
control) as candidate biomarkers for babies with perinatal asphyxia 
 
Results: 
Study Population: 
Between January and August 2014, 30 newborn babies were recruited from two 
centers. 
From the 30 newborns studied, 19 were selected for therapeutic hypothermia on the 
basis of standard cooling criteria (22) and 11 infants with perinatal acidosis and no 
encephalopathy were managed conservatively.  
 
MRI/Clinical Outcome:  
Of the 30 babies, 19 had MRI performed between 5 to 35 days (median = 9 days) of life. 
The pattern of cerebral tissue injury noted on MRI was scored using the system 
described by Rutherford and colleagues (23). Based on MRI and/or short term clinical 
outcome at discharge, 23 babies were predicted to have a favorable outcome and 
seven were predicted to have an unfavorable outcome. The favorable outcome group 
had 10 babies with normal neurological examination at discharge and no MRI 
performed, eight babies with normal MRI scans and five babies with minor changes on 
MRI. The unfavorable outcome group comprised of five babies with severe changes in 
MRI, one baby who died on second day of life with multi-organ failure associated with 
severe hypoxia-ischemia, and a baby with severely abnormal neurological examination 
at discharge and having on-going investigations for a neurologic diagnosis. Overall, 19 
babies were treated with therapeutic hypothermia (n=13 in favourable group; n=6 in 
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unfavorable group). Table 1 describes the baseline characteristics of all babies based 
on their predicted outcome group. 
 
Total RNA concentration: 
Total RNA concentration values (mean ± SEM) were 11.1 ± 1.6 ng/µl for all biosamples 
and 10.6 ± 2.5 ng/µl for DBS alone. The RNA quality values of 260/280 (mean ± SEM) 
were 1.68 ± 0.04 and 1.77 ± 0.05 for all and DBS samples, respectively (Figure 1) 
which represent similar quality of RNA from all biofluids.  
 
MiRNA expression: 
Three of the miRNAs examined (RNU6B, Let7b and miR-21) were expressed in a 
majority of the biosamples (plasma, EDTA -blood, urine and DBS) from the babies. In 4 
out of 30 plasma and 8 out of 30 urine samples, RNU6B miRNA was not detectable. 
Correlations were carried out for the expression of RNU6B, Let7b and miR-21 miRNAs 
in all biofluids with DBS. There was a significant positive correlation between DBS and 
EDTA-blood for RNU6B, let7b and miR-21(Figure 2). There was no statistically 
significant correlation between the DBS with plasma or urine. The comparison of miRNA 
expression in different biosamples using mean cyclical threshold (Ct) values from three 
technical replicates for all three miRNAs analyzed demonstrated significantly lower Ct 
values (i.e., higher expression) in DBS than in plasma, EDTA-blood and urine in the 3 
selected miRNAs studied: RNU6B, Let7b and miR-21 (Figure 3). We also observed 
from the variable times (range 2 to 191 days) in extraction of total RNA from the point of 
sample collection, it was still possible to extract the selected miRNAs from all samples 
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after prolonged storage (data not shown). This was true for all biosamples; plasma, 
EDTA-blood, urine stored at -80 oC and DBS stored in room temperature. 
 
MicroRNAs in HIE: 
To study the role of microRNAs in HIE, five neuro-specific miRNAs (Let7b, miR-21, 
miR-29b, miR-124 and miR-155) were selected. The Ct values were converted to delta 
Ct, which represents values normalized to a putative endogenous control RNU6B. 
There was no significant difference noted between the favorable and the unfavorable 
outcome groups in the delta Ct values of all candidate miRNAs studied, i.e., Let7b, 
miR21, miR-29b, miR-124 and miR-155 in DBS (Figure 4). It was also noted that delta 
Ct values were not different between the outcome groups in other biosamples (plasma, 
EDTA -blood and Urine) for Let7b and miR21. 
 
Discussion: 
To our knowledge, this is the first study to demonstrate that it is feasible to extract 
sufficient quantity and quality miRNAs in newborns from a single 6 mm diameter DBS 
stored at room temperature and in quantities significantly higher than in other common 
biosamples, including plasma, urine and blood for analysis of similar total RNA 
concentration and quality. We also showed that it was possible to extract total RNA and 
study the expression of miRNA from DBS stored at room temperature for up to 6 
months from the time of sample collection. The quantity and quality of RNA, and all 
candidate miRNAs extracted from DBS were all similar to those from other biofluids 
after prolonged storage at -80 oC.   
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RNU6B is a small nucleolar miRNA, and generally low or not expressed in plasma in 
adults (24). On the contrary, we noted that RNU6B was expressed in most of our 
plasma samples apart from a small proportion. Presence of RNU6B in most plasma 
samples could be explained by the hemolysis noted in a significant proportion of our 
plasma samples (24). Furthermore, it has been noted that there is an increase in 
nucleated red blood cells in babies in HIE (25). We also noted RNU6B in most of our 
urine samples, and this may be due to cells in the urine, as uncentrifuged urine was 
used in this study.  
 
There was positive correlation between EDTA-blood and DBS for all miRNAs examined. 
There were significantly lower Ct values for RNU6B, let7b and miR-21 observed in DBS 
compared to plasma, blood and urine, implying a higher expression of miRNAs in DBS 
compared to other biosamples. This may be related to the DBS representing both intra 
and extracellular components of blood.  There has recently been much interest in tissue 
biomarkers in the study of CNS pathology in adults (26). DBS have been routinely used 
in universal screening programs in newborns in the first week after birth for early 
detection of diseases (3). Recently, Buroker et al (27) have successfully extracted 
miRNAs from two 1.5 cm diameter DBS which had been stored at -80 oC. Bartha and 
co-workers (28) studied cytokines and tumor necrosis factor alpha from DBS by 
immunoaffinity chromatography in babies with neonatal encephalopathy. These 
samples were stored at -26 oC before analysis. We were able to extract sufficient 
quantity and quality of miRNAs from a single 6 mm diameter spots from newborns 
stored at room temperature. One potential reason for our success is that the DBS was 
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dried completely after collection, and studies indicate that humidity may affect miRNA 
preservation (29). 
 
In our study, despite our best efforts to ensure that all blood samples were free flowing, 
hemolysis was noted in some of the EDTA samples, albeit minimally (data not shown). 
McDonald et al (30) showed that hemolysis increased apparent concentration of some 
but not all miRNA levels on pre-analytical variables in extraction of miRNA.  Additionally, 
the time from collection of the blood sample to centrifuge, and then storage at -80 oC, 
was variable due to difficulty in access to the laboratory round-the-clock in our study. It 
has been shown that delay in centrifuging up to 6 h affected the levels in some 
candidate miRNAs studied significantly (31). Therefore, our miRNA extraction from 
plasma could have been affected due to delay in centrifuging some samples. Most 
studies on miRNAs have used serum or plasma. However, miRNAs can also be 
released during cell death as apoptotic bodies or bound to proteins like Ago2 and 
lipoproteins (32). Therefore in pathologies involving cell injury like perinatal asphyxia, it 
is potentially more valuable to study whole blood in the form of DBS and not just the 
extracellular components found in serum/plasma. Furthermore, DBS provided highest 
expression of miRNA given that 10ng of total RNA was equally loaded for all 
biosamples.  
 
Limitations of our study include the variation in age after birth when the biosamples 
were obtained from the newborns. This was limited by age when infants were 
transferred from other hospitals, the time taken for parents to give informed consent and 
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the availability of research staff to take and process the samples. Our results did not 
show a variation in the expression levels of the control miRNA in relation to sampling 
time from birth. It is well recognized that there is a temporal variation in many 
biomarkers of brain injury in newborns after birth (33). In future studies, serial sampling 
from each baby to analyze the natural history of these biomarkers associated with 
varying degrees of brain injury will be carried out. Due to lack of serial testing with the 
same sample across various time points, it is not possible to comment on the stability of 
the RNA and miRNAs over time in the DBS and other biosamples from this study. 
Although the quality values of the total RNA extracted were not within the expected 
value of 2.0 when analyzed with the NanoDrop spectrophotometer, this was likely due 
to the circulating RNases present in the biosample which can degrade large RNAs into 
small RNAs (34). Li and Kowdley have shown that , clinical serum samples contain 
mainly small RNA molecules, including microRNAs with the absence of large RNA 
species, such as messenger RNA and ribosomal subunits 18S and 28S when RNA 
quality was determined using the Agilent 2100 Bioanalyzer (34). Due to the absence of 
18S and 28S subunits, it is not possible to perform RNA integrity number for 
determining the quality of the total RNA in the samples (34). In this study, the mirVana 
PARIS RNA extraction kit which involves the strategy of combining denaturing reagents 
and a silica filter was used. This RNA extraction kit has been shown to successfully 
extract miRNAs with least miRNA degradation and high miRNA quality in comparison to 
other commercially tested kits (34). 
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In this small cohort, we were not able to show any difference in the selected candidate miRNA 
expression in the unfavorable prognosis group compared to the favorable prognosis group. 
Larger  studies exploring more candidate miRNAs at serial time points in babies presenting with 
perinatal asphyxia are required to understand the role of specific miRNAs expression in HIE.  
 
Conclusions: We demonstrate that it is feasible to study the expression of miRNA from a very 
small sample of DBS obtained from newborns. MiRNA expression from DBS correlates 
well with those from EDTA-blood. DBS is relatively cheap, technically easier to obtain in 
all age groups, especially in small and sick neonates and simpler for transportation and 
storage. This also eliminates potential sources of error, common in the pre-analytical 
stage, associated with blood collection and centrifuging. This novel method using a very 
small drop of blood as DBS has a potential for use in future studies to explore further 
the role of miRNAs as possible biomarkers in neonates.   
 
Methods: 
Infant recruitment and selection 
The study received Research and Ethics approval (REC 13/LO/1738) from National 
Research Ethics Committee, London and informed written consent was obtained from 
the parents of recruited participants. Newborn babies were recruited from two tertiary 
neonatal centers in London; the Royal London Hospital and Homerton University 
Hospital. Babies were recruited to the study if (i) they were ≥36 weeks gestation, fulfilled 
standard cooling criteria (22) and were selected for mild hypothermia for 
neuroprotection by the attending clinicians (cooled group) or (ii) infants who were 
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admitted to the neonatal unit for conservative management with suspected milder 
hypoxia-ischemia on the basis of metabolic acidosis but did not fulfill the criteria for 
cooling treatment (non cooled - mild group). Infants with multiple congenital 
abnormalities or confirmed inborn error of metabolism were excluded.  
 
Biosamples: 
The biosamples chosen for determining miRNA expression levels were plasma, EDTA-
blood, urine and DBS collected at a median time of 18-19 hours of age in both groups 
and after the infants in the cooled group had reached their target core temperature (33.5 
oC). Of the 1.5 ml of blood obtained from the newborn, one drop was placed on 
absorbent filter paper (Whatman 903 protein saver card, GE Healthcare life sciences, 
Little Chalfont, UK) creating a dried blood spot. This was allowed to dry at room 
temperature and was then stored in a polythene bag with a packet of desiccant to 
sustain desiccation. The remaining blood was transferred into tubes with sprayed-
coated K2EDTA (Fisher Scientific Ltd, Loughborough, UK) and then centrifuged at 
15,000 x g for 10 minutes to separate the plasma and blood components (EDTA-blood). 
The plasma, EDTA-blood, and urine collected from a bag or a catheter sample were all 
stored at -80 oC until further processed. 
 
RNA extraction 
MirVana PARIS isolation kit (Ambion, Life technologies, Paisley, UK) was used to 
extract total RNA from 50 µl plasma, 50 µl urine, 1 µl of blood sample withdrawn using a 
23G needle, and a single 6 mm diameter chad from the center of DBS was collected 
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using a clean single hole puncher.  Total RNA isolation was carried out according to 
manufacturer’s instruction. Briefly, biosamples were suspended in cell disruption buffer 
to a final volume of 300 µl and vortexed for 10 seconds. The blood in the DBS was 
resuspended by pipetting up and down using a 1ml pipette tip, then transferring the 
supernatant to a clean tube. After the samples were mixed with denaturing solution, 
acid phenol:chloroform mixture was added, vortexed, then centrifuged at 15,000 x g, for 
5 minutes at room temperature. The top aqueous layer was carefully collected and 
mixed with 100% ethanol. The total RNA was collected in a filter cartridge, washed, and 
eluted using 100 µl of 95 oC pre-heated elution buffer. Using the NanoDrop 1000 
spectrophotometer, the concentration and quality of the total RNA in all samples were 
analyzed and recorded. All RNA samples were stored at -80 oC until further processed. 
 
TaqMan microRNA assay 
TaqMan microRNA assays (Life technologies) for RNU6B , let7b, miR-21, miR-29b, 
miR-124 and miR-155 were used, which involved the reverse transcription of miRNA 
followed by a singleplex TaqMan assay reaction performed using real-time PCR 
amplification.  Briefly, 10 µg of total RNA was reverse transcribed using the TaqMan 
MicroRNA Reverse Transcription kit (Applied biosystems, Life technologies) which 
contained 1x RT buffer, dNTPs with dTTP, RNase inhibitor and MultiScribe Reverse 
Transcriptase enzyme and reaction was carried out in a thermal Cycler at 16 °C for 30 
minutes, 42 °C for 30 minutes, 85 °C for 5 minutes and 4 °C for holding. The 
quantitative PCR amplification was performed using the TaqMan Fast Universal PCR 
Master Mix (2X), no AmpErase UNG (Applied biosystems, Life technologies), TaqMan 
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small RNA assay and RT reaction product. The reaction samples (20 µl) were loaded in 
triplicates into a 96 well plate. Using the Applied Biosystems 7500 Fast Real-time PCR 
system, the thermal cycling conditions were: hold at 50 ºC for 2 minutes, then at 95 ºC 
for 10 minutes, and then 40 cycles of denature at 95 ºC for 15 seconds and 
anneal/extend at 60 ºC for one minute. The results were represented as Ct values. Ct 
values denote the cyclical threshold in polymerase chain reactions, in which lower Ct 
values indicate higher expression as a result of amplification in earlier cycles due to 
abundance of the nucleic acid in the sample. 
 
Outcomes 
MR images were independently rated by a neuroradiologist (JE) and a neonatologist 
with expertise (OK). The pattern of MRI injury was classified into two groups using the 
system described by Rutherford et al., which has prognostic value in infants who have 
undergone therapeutic hypothermia (23). Infants with an unfavorable outcome had a 
severe pattern of injury including; reversed or abnormal signal intensity bilaterally on T1 
and or T2 weighted sequences in the posterior limb of the internal capsule; multifocal or 
widespread abnormal signal intensity in the basal ganglia and thalami; or severe 
widespread white matter lesions including infarction, hemorrhage and long T1 and T2. 
Infants with MRIs predictive of a favorable outcome had either normal images or less 
severe patterns of injury that are associated with normal or mildly abnormal 
neurodevelopmental outcome. Consensus was reached in cases of disagreement. 
Infants who died prior to MR imaging were classified in the unfavorable outcome group. 
Infants who were not cooled were classified as having a favorable outcome if they had a 
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normal neurologic examination at 24 hours age and were discharged home on suck 
feeds. These infants did not have MR imaging.  
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Table 1: Baseline characteristics of all babies according to predicted outcome 
 
Perinatal characteristics Favorable outcome 
n = 23 
Unfavorable outcome 
n = 7 
Gestational age,  
(completed weeks + days) 
39+6 (37+2 to 42+4) 40 (35+6 to 41+1) 
Male sex, n (%) 12 (52%) 7 (100%) 
Birth Weight (grams) 3360 (2000 - 4280) 3504 (2200- 3840) 
Apgar score at 10 min 7 (0 - 10) 5 (0 -9) 
Worst pH  within 1 hr 6.9 (6.48 - 7.30) 6.9 (6.86 - 7.32) 
Worst base deficit within 1 hr -16.1 (-6.4 to -35) -19.3 (-12.3 to -19.5) 
Need for respiratory support at 10 min 
age, n (%) 
12 (52%) 6 (86%) 
Need for chest compressions, n (%) 5 (21%) 3 (33%) 
Antenatal sentinel event present, n (%) 7 (37%) 2 (18%) 
 
 
Values are median (range) unless indicated otherwise 
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Figure 1: RNA extraction: quantity and quality in all 4 biosamples. (a) Total RNA 
extracted from newborns with HIE showed similar average total RNA concentration as 
measured in ng/µg. (b) Average total RNA quality in plasma, blood, urine and DBS 
measured as a 260/280 ratio. NS, non-significant (P>0.05) using one way ANOVA with 
Tukey post hoc test. Data are presented as mean ± s.e.m. 
 
Figure 2: Expression of miRNAs in DBS compared to plasma, blood and urine 
biosamples. (a-c) Comparison of RNU6B Ct values in DBS to other biosamples. (d-f) 
Comparison of Let7b Ct values in DBS to other biosamples. (g-i) Comparison of miR-21 
Ct values in DBS to other biosamples. Graphs b, e and h demonstrate significant co-
efficient of determination (R2) values for blood and DBS in all 3 miRNAs: RNU6B, R2  = 
0.270; Let7b, R2 = 0.503; miR-21, R2 = 0.202. * P<0.05, **P<0.01, † P<0.001 indicate 
significance of R2 between biosamples. 
 
Figure 3: Expression of miRNAs in all 4 biosamples.  
Expression of (a)  RNU6B, (b) Let7b and (c) miR-21 in all 4 biosamples (each 
performed in technical triplicates). * P<0.05, ** P<0.01, † P<0.001 indicate significance 
between biosamples; NS, non-significant (P>0.05) using one way ANOVA with Tukey 
post hoc test. Data are presented as mean ± s.e.m. 
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Figure 4:  Comparison of normalized expression of selected candidate miRNAs in DBS 
between favourable and unfavorable outcomes. Mean delta Ct values in DBS for 
various miRNAs are shown in the graphs: (a) Let7b, (b) miR-21, (c) miR-29b, (d) miR-
124 and (e) miR-155. The p values did not show any significant difference between the 
favourable and unfavorable outcome groups in for all miRNAs. NS, non-significant 
(P>0.05) using Student’s t-test. Data are presented as mean ± s.e.m. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
 
 
